Trial Profile
A 12 week, randomized, double blind parallel group prospective dose ranging study of ZYH1 with an open fenofibrate arm to evaluate the efficacy on dyslipidemia in patients without diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary) ; Fenofibrate
- Indications Dyslipidaemias
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cadila Healthcare
- 12 Mar 2010 New trial record